MentalHealthDaily

Genetic (Polygenic) Risk for Psychiatric Disorders & Subject-Specific School Grades (2023 Study)

by GLOOM

The intricate connection between mental health and educational attainment is a subject of growing interest and importance. Recent studies have shed light on how genetic predispositions to certain mental disorders can influence academic performance, challenging our understanding of how mental health impacts learning. Highlights: Polygenic Risk Scores Reveal New Insights: Studies utilizing polygenic risk scores …

Can Lifestyle Factors Modify Risk of Psychiatric Disorders? (2024 Study)

by GLOOM

Psychiatric disorders have increasingly become a significant public health concern, affecting a growing number of people globally. A study in focus utilized MR (Mendelian randomization), a method that leverages genetic data to explore causal relationships, to analyze the impact of 45 lifestyle factors on 13 psychiatric disorders. This extensive research involved GWAS summary statistics from …

Detecting Misdiagnosed Bipolar Disorder via MRI Brain Connectivity Analysis (2024 Study)

by GLOOM

Bipolar Disorder (BD) and Major Depressive Disorder (MDD) are two of the most prevalent mood disorders, yet they are often misdiagnosed due to overlapping symptoms. This misdiagnosis can lead to inadequate treatment and worsened patient outcomes. However, recent advances in functional magnetic resonance imaging (fMRI) offer a promising solution to this challenge. By analyzing brain …

Non-Invasive Brain Stimulation for Bipolar Disorder: Effective & Tolerable in Early Studies (2023)

by GLOOM

Non-invasive brain stimulation (NIBS) presents a promising frontier for treating bipolar disorder, offering potential alternatives or adjuncts to conventional pharmacotherapy. Emerging evidence suggests that certain non-invasive brain stimulation protocols may help manage symptoms of bipolar disorder. Highlights: Efficacy: Certain NIBS modalities, like anodal tDCS over F3 plus cathodal tDCS over F4, have shown significant improvement …

Antidepressants May Trigger Mania In Bipolar Disorder via Mitochondria

by GLOOM

Antidepressants, commonly used to treat major depressive episodes in bipolar disorder, might have more profound effects on our body’s energy factories, the mitochondria, than previously understood. A recent study examined how certain antidepressants alter mitochondrial energetics, potentially influencing the risk of treatment-emergent mania in bipolar disorder patients. Highlights: Antidepressants Double Edged Sword: While crucial for …

Adjunct Celecoxib for Depression & Mania: Treatment with a COX-2 Inhibitor

by GLOOM

Celecoxib, a selective COX-2 inhibitor, shows promise as an effective and safe adjunct treatment for major depression and mania, according to a new comprehensive systematic review. The analysis also found celecoxib improved symptoms when used as a standalone antidepressant in patients with somatic disorders. However, evidence for efficacy in bipolar depression remains unclear. Key Facts: …

Vraylar (Cariprazine) Approved For Schizophrenia & Bipolar Disorder

by GLOOM

Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder. In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient. The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …